Myriad's BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Talazoparib in Metastatic Breast Cancer https://t.co/5YmSrkCbHI
The Food and Drug Administration (FDA) approved the first treatment specifically for advanced #BreastCancer associated with #BRCA gene mutations. https://t.co/1yfnysOX66
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Metastatic #BreastCancer https://t.co/k65qwsCzqd
AstraZeneca has expanded its agreement with US group Myriad Genetics to identify women with advanced #OvarianCancer most likely to benefit from its medicines https://t.co/elNUy3Duop
We're excited to partner with @AstraZeneca with this new companion diagnostic collaboration to enhance #PrecisionMedicine in a clinical trial for patients w/ #ovariancancer https://t.co/VI6vLS1QJN
PARP inhibitors are an exciting step forward in expanding the role of #PrecisionMedicine and improving outcomes for patients with #BreastCancer https://t.co/6HQeAhfoeP
NCCN has recognized the important role that #BRCA testing plays in identifying which patients are likely to benefit from olaparib treatment https://t.co/6HQeAhfoeP
Exciting news for patients with metastatic #BreastCancer! Olaparib is now recommended as a preferred single agent for treatment of patients with HER2-negative, #BRCA 1/2-positive tumors https://t.co/6HQeAgXMQf